Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2017 | 12-2016 | 09-2016 | 12-2015 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -6,411 | -32,640 | -24,444 | -13,150 |
| Depreciation Amortization | 87 | 270 | 194 | 10 |
| Accounts payable and accrued liabilities | -82 | N/A | -679 | N/A |
| Other Working Capital | 482 | -790 | -254 | 170 |
| Other Operating Activity | -1,055 | 4,210 | 5,428 | 3,370 |
| Operating Cash Flow | $-6,979 | $-28,950 | $-19,755 | $-9,600 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | N/A | -830 | -569 | -230 |
| Investing Cash Flow | $N/A | $-830 | $-569 | $-230 |
| Cash Flows From Financing Activities | ||||
| Other Financing Activity | 43,001 | 34,410 | 25,913 | 15,270 |
| Financing Cash Flow | $43,001 | $34,410 | $25,913 | $15,270 |
| Beginning Cash Position | 10,365 | 5,690 | 5,691 | 250 |
| End Cash Position | 46,387 | 10,310 | 11,280 | 5,690 |
| Net Cash Flow | $36,022 | $4,620 | $5,589 | $5,430 |
| Free Cash Flow | ||||
| Operating Cash Flow | -6,979 | -28,950 | -19,755 | -9,600 |
| Capital Expenditure | N/A | N/A | -569 | N/A |
| Free Cash Flow | -6,979 | -28,950 | -20,324 | -9,600 |